Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform and removed the firm’s price target on the shares after the company announced that VERITAC-2 had missed on the all-comers co-primary ...

On Tuesday, Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an Outperform rating. This heightened optimism is driven by positive ...

Oppenheimer noted that the trial results address market skepticism that emerged following initial data released last September, prior to changes that aligned the trial design more closely with current ...

Annovis Bio's CEO to present at Oppenheimer's conference, discussing Phase 3 trial progress and NDA initiatives for buntanetap. Annovis Bio Inc. has announced that its CEO, Dr. Maria Maccecchini, will ...

Please contact your Oppenheimer representative to register for the Movers in Rare Disease Summit and to schedule a 1x1 meeting with Dr. Mor and Chemomab management.